Table 11 Subgroup analysis of the included randomized controlled trials

TG

TC

LDL

Number

Combined Effect Value

Heterogeneity

Number

Combined Effect Value

Heterogeneity

Number

Combined Effect Value

Heterogeneity

SMD (95%CI) mmol/L

I²

SMD (95%CI) mmol/L

I²

SMD (95%CI) mmol/L

I²

overall

15

-0.66(-1.17, -0.16)*

89.50%

14

-0.43(-0.86, -0.01)*

81.90%

13

-0.44(-0.88, -0.01)*

83.00%

Totals

 ≥ 50

5

-0.83(-1.08, -0.58)*

85.90%

5

-0.65(-1.02, -0.01)*

58.90%

5

-0.56(-1.02, -0.11)*

73.40%

 < 50

10

-0.41(-0.62, -0.2)*

93.70%

9

-0.35(-1.07, 0.38)

85.70%

8

-0.46(-1.19, 0.27)

86.30%

Age

 ≥ 50

8

-0.29(-0.5, -0.08)*

64.80%

7

-0.18(-0.55, 0.2)

58.70%

7

-0.15(-0.65, 0.35)

76.20%

 < 50

7

-1.02(-1.28, -0.77)*

93.60%

7

-0.93(-1.76, -0.09)*

88.80%

6

-0.93(-1.71, -0.15)*

87.90%

Dosage

 ≥ 1000

4

-1.41(-1.7,-1.13)*

94.40%

3

-0.53(-1.32, 0.19)

78.10%

2

-0.36(-1.16, 0.45)

80.90%

 < 1000

8

-0.17(-0.4, 0.06)

74.10%

8

-0.47(-1.17, 0.22)

86.60%

8

-0.63(-1.36, 0.1)

88.00%

Duration

 ≥ 10w

13

-0.51(-0.69, -0.34)*

89.50%

13

-0.37(-0.82, 0.07)

81.90%

12

-0.40(-0.86, 0.07)

 < 10w

2

-1.09(-1.54, -0.64)*

92.50%

2

-1.09(-1.66, -0.52)*

1

-0.99(-1.55, -0.43)*

83.30%

Dietary intervention

 none

-1.82(-3.66, 0.03)

91.90%

3

-10.22(-29.81, 9.37)

97.30%

2

-4.70(-13.54, 4.14)

96.90%

 regular

-0.40(-0.70, -0.11)

44.30%

5

-0.55(-0.90, -0.21)

44.70%

5

-0.54(-0.97, -0.12)

64.40%

 advised

-0.46(-1.61, 0.69)

94.30%

6

-0.16(-0.67, 0.35)

74.40%

6

-0.07(-0.62, 0.48)

77.70%

Oral form

 row

1

-0.54(-1.07, 0.00)

1

'-1.09(-1.66, -0.53)

1

'-0.99(-1.55, -0.43)

 aged

2

-0.68(-1.20, -0.17)

54.30%

1

'-0.23(-0.76, 0.30)

1

'-0.05(-0.58, 0.48)

 produced

12

-0.69(-1.36, -0.01)

91.60%

13

'-0.40(-0.90, 0.10)

83.40%

11

'-0.45(-0.97, 0.07)

84.60%

HDL

SBP

DBP

Number

Combined Effect Value

Heterogeneity

Number

Combined Effect Value

Heterogeneity

Number

Combined Effect Value

Heterogeneity

SMD (95%CI) mmol/L

I²

SMD (95%CI) mmol/L

I²

SMD (95%CI) mmol/L

I²

overall

15

0.1(-0.28, 0.48)

82.80%

9

-0.56(-1.58, 0.47)

95.1

9

-1.33(-2.14, -0.53)*

92.10%

Totals

 ≥ 50

5

0.45(0.08, 0.82)*

61.50%

2

-6.52(-19.26, 6.23)

95.10%

2

-9.42(-26.77, 7.94)

98.50%

 < 50

10

-0.09(-0.66, 0.47)

86.10%

7

0.27(-0.71, 1.25)

93.50%

7

-0.83(-1.39, -0.26)*

81.70%

Age

 ≥ 50

8

0.33(-0.16, 0.81)

80.10%

6

-1.51(-2.65, -0.37)*

94.10%

6

-1.52(-2.62, -0.43)*

93.30%

 < 50

7

-0.16(-0.79, 0.46)

86.00%

3

1.64(-0.92, 4.20)

97.00%

3

-1.19(-2.61, 0.23)

92.30%

Dosage

 ≥ 1000

4

0.42(-0.47, 1.31)

91.40%

2

2.25(-4.65, 9.16)

98.80%

2

-1.23(-2.21, -0.26)*

92.30%

 < 1000

8

-0.15(-0.64, 0.34)

76.60%

7

-1.08(-2.03, -0.12)*

92.30%

7

-1.83(-3.59, -0.07)*

92.10%

Duration

 ≥ 10w

13

0.14(-0.28, 0.55)

83.10%

7

-0.42(-0.85, 0.01)

73.10%

7

-0.59(-0.90, -0.29)*

46.30%

 < 10w

2

-0.10(-1.32, 1.12)

88.30%

2

-3.60(-22.14, 14.94)

99.20%

2

-10.45(-25.76,4.86)

98.10%

Dietary intervention

 none

3

-0.92(-1.69, -0.16)

65.00%

2

2.53(-3.85, 8.90)

98.50%

-1.80(-3.65, 0.04)

91.70%

 regular

6

0.42(-0.02, 0.86)

74.60%

3

-3.82(-6.62, -1.03)

97.40%

-4.33(-7.18, -1.48)

97.30%

 advised

6

0.26(-0.36, 0.88)

82.50%

4

-0.23(-0.62, 0.16)

34.90%

-0.54(-0.90, -0.19)

20.80%

Oral form

 row

1

0.51(-0.03, 1.05)

-

-

-

-

-

-

-

 aged

2

0.88(-0.03, 1.79)

84.60%

2

-7.07(-18.71, 4.56)

98.30%

2

-9.56(-26.63, 7.52)

98.50%

 produced

12

-0.07(-0.49, 0.35)

80.30%

7

0.41(-0.48, 1.29)

91.90%

7

'-0.78(-1.35, -0.22)

81%